Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
Condition(s) studied
Investigational drug(s) / intervention(s)
Berberine: The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
Healthy lifestyle intervention: Healthy lifestyle intervention will be launched according to the "Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019", including health lectures, health information promotion, health manual and so on.
Study summary
The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).
Eligibility
Primary outcome measure(s)
- Rate of composite cardiometabolic endpoints — three year
The composite endpoints including cardiac death, nonfatal myocardial infarction, nonfatal stroke, and newly-diagnosed type 2 diabetes.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University Third Hospital | Beijing | Beijing Municipality |
More Tang Yida trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05105321 on ClinicalTrials.gov ↗ ← All trials in China